Khavinson Bioregulator Peptides: Origins, Sequences and an Honest Look at the Evidence

Bioregulators are among the most catalogued and least independently tested compounds in peptide research, and the claims around them often run well ahead of the data. They are also genuinely interesting: the hypothesis is specific and testable in a way much peptide folklore is not. This guide covers their origins, the proposed mechanism, each compound, and how much weight the evidence will bear. Each compound's own article is linked from the table.

Origins: military medicine and organ extracts

The programme began in 1973 at the S.M. Kirov Military Medical Academy in Leningrad. In Khavinson's own history of the work, the aim was to raise the resilience of military personnel exposed to radiation, toxic substances, injury, hypoxia and severe stress. With Vyacheslav Morozov he started with the thymus and the pineal gland, organs whose function was thought to be suppressed by stress [1].

The first products were cytomedins: peptide mixtures obtained from animal organs by mild acid extraction [1, 2]. Thymalin, from calf thymus, was introduced in 1982, followed by Epithalamin from the pineal gland in 1990 and Cortexin from the cerebral cortex in 1999. Each is a complex of peptides up to about 10 kDa rather than a defined molecule [1].

Extracts are hard to standardise and do not reveal which component does the work, so the second phase looked for short sequences to stand in for each one. Some were designed from an extract's amino acid composition; others were reported as detected inside it by mass spectrometry. All were made synthetically, and the group calls them cytogens [3]. Vilon and Crystagen were linked to Thymalin, Epitalon to Epithalamin, Cortagen and Pinealon to Cortexin, and others to extracts of blood vessel, heart, bronchus, liver, pancreas, cartilage and testis [1]. The work continued at the St Petersburg Institute of Bioregulation and Gerontology, the source of most of the literature discussed here.

The bioregulators at a glance

Sequences below were checked against the group's reviews and primary papers (references 1, 2 and 4 to 10). The tissue association is the one the originating group assigns, usually the organ whose extract a sequence came from: a label from the framework, not an independently established property.

* One 2014 paper from the group writes this peptide as Ala-Asp-Glu-Leu [10]; the group's reviews, including one that cites that paper, give Ala-Glu-Asp-Leu [4].

Two features matter later. Fourteen of the fifteen defined sequences share a Glu-Asp pair, and some differ by one residue: Epitalon and Cortagen only at the final position, as do Testagen and Prostamax. The labels are also looser than they look: Pinealon, despite its name, was reported in the cortex extract Cortexin and is studied mainly in neurons.

The proposed mechanism

Most therapeutic peptides act on receptors at the cell surface. The bioregulator model proposes something different: peptides of two to four residues cross the cell and nuclear membranes, bind particular DNA sequences in gene promoters or the tails of histone proteins, and so change how tightly chromatin is packed and which genes are read [4]. Three kinds of work are offered in support.

• Uptake and binding. Fluorescently labelled Epitalon, Pinealon and Testagen appeared in the nucleus and nucleolus of HeLa cells, and in solution the peptides appeared to bind DNA fragments with preferences that depended on sequence and methylation [11]. Spectroscopy and viscometry placed Bronchogen in the DNA major groove [10].
• Chromatin and gene expression. Epitalon loosened condensed heterochromatin and reactivated ribosomal genes in cultured lymphocytes from people aged 76 to 80 [12]. In mouse heart, Cortagen changed the expression of 234 transcripts, despite being assigned to the brain cortex [5].
• Modelling. A 2019 docking and molecular dynamics study, with Khavinson as a co-author, screened every possible dipeptide against double-stranded DNA. Most could not bind at all; 57 formed low-energy, sequence-selective complexes, and the authors calculated that selectivity can rise sharply with peptide length [13].

What independent scientists say

Outside the originating network the mechanism has had little direct testing, so the wider field has largely neither confirmed nor refuted it. Recent cell studies with Italian universities include Khavinson as an author [9], so they are collaborations rather than independent checks. What independent work exists points both ways.

The broad idea is chemically plausible and not unique to St Petersburg. In 1975 an Italian group described a small peptide factor from calf thymus that inhibited DNA transcription in vitro through electrostatic binding to DNA [14].

The clearest independent replication tested a downstream claim. In 2003 Khavinson's group reported that Epitalon switched on telomerase in human fetal fibroblasts [15]. In 2025 a Brunel University London team found that Epitalon lengthened telomeres in normal human fibroblast and epithelial cells through increased hTERT expression and telomerase activity, broadly consistent with that report. In two breast cancer cell lines, however, telomeres lengthened mainly through the alternative lengthening of telomeres (ALT) pathway, a finding with obvious safety relevance, and all of the work was in cell culture [16].

A 2025 review from the Medical University of Warsaw, also independent, noted that after 25 years of biological studies Epitalon's physicochemical and structural characterisation is still limited, and that toxicity, genotoxicity and carcinogenicity data would be needed before it could be developed as a medicine [17].

The central scientific objection is specificity. Sequence-specific DNA recognition is normally the work of proteins that contact several base pairs across a large surface; a peptide of two to four residues offers very few contacts, and these peptides are strikingly alike. The open question is not whether such a peptide can touch DNA in a test tube but whether it can pick out particular genes, at realistic concentrations, in living tissue. Two methodological points sharpen it: the fluorescein label in the uptake experiments is roughly as heavy as the peptide carrying it, and most binding data come from purified DNA or computer models.

An honest evidence assessment

Four features define this literature.

• One network. The great majority of studies come from Khavinson's institute and long-standing collaborators in St Petersburg, Moscow, Kyiv and Tbilisi. Collaboration is normal in science; the gap is that very little has been repeated by groups with no connection to the originators.
• Language and access. Much of the primary literature appears in Russian-language journals such as Advances in Gerontology (Uspekhi Gerontologii), and the papers that give the Livagen and Prostamax sequences used here have English abstracts only [6, 7]. Most English-language readers meet the work through summaries that drop the caveats.
• Mostly cells and rodents. Even here, results are more modest than summaries suggest. In the best-known mouse study, Epitalon did not change mean lifespan, food intake or body weight in female SHR mice. It was associated with longer survival in the longest-lived tenth of animals and with less leukaemia, while total tumour incidence was unchanged [18].
• Little human data, mostly on extracts. The most cited human study followed 266 older people in St Petersburg and Kyiv for six to eight years and reported lower mortality in groups given Thymalin, Epithalamin or both than in controls [19]. It concerned the extracts, not the synthetic peptides; its abstract does not describe randomisation or blinding; and we found no repeat by an unaffiliated group. For synthetic Epitalon, the Warsaw review's section on clinical trials describes two studies: one in 162 people with retinitis pigmentosa, run at the St Petersburg institute, and one in 75 women measuring melatonin and clock gene expression [17].

Tissue specificity deserves its own caveat. It rests mainly on the group's explant studies, in which each synthetic peptide stimulated growth of the tissue its parent extract came from [3]. Yet the group's 2021 review classes Epitalon, Vesugen and several others as polyfunctional, with reported effects across many cell types [4]. The organ names are best read as a record of where each sequence came from, not proof of where it acts.

The bottom line

Bioregulators are a coherent hypothesis resting on a large, mostly single-source literature. The chemistry is plausible and one cell finding has partly held up in independent hands, while the human evidence is thin and mostly concerns extracts. When a claim about a bioregulator sounds unusually confident, it is worth asking whether the confidence came from the study or from the summary.

Related reading

• Bioregulator research range
• Cognitive peptides from the Russian research tradition
• Thymosin alpha-1 and thymic peptide research
• How to verify a peptide COA
• Independent lab tests
• Research library

References

1. Khavinson VKh. 2020. "Peptide medicines: past, present, future" (in Russian). Klinicheskaya Meditsina 98(3):165-177. doi:10.30629/0023-2149-2020-98-3-165-177
2. Morozov VG, Khavinson VK. 1997. "Natural and synthetic thymic peptides as therapeutics for immune dysfunction." International Journal of Immunopharmacology 19(9-10):501-505. PMID 9637345
3. Khavinson VK. 2001. "Tissue-specific effects of peptides." Bulletin of Experimental Biology and Medicine 132(2):807-808. PMID 11713572
4. Khavinson VK, et al. 2021. "Peptide Regulation of Gene Expression: A Systematic Review." Molecules 26(22):7053. PMID 34834147
5. Anisimov SV, et al. 2004. "Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray." Neuro Endocrinology Letters 25(1-2):87-93. PMID 15159690
6. Brodskii VIa, et al. 2001. "Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen" (in Russian). Izvestiia Akademii Nauk, Seriia Biologicheskaia (5):517-521. PMID 15926314
7. Dzhokhadze TA, et al. 2012. "Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)" (in Russian). Georgian Medical News (212):76-82. PMID 23221144
8. Zakutskii AN, et al. 2006. "The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats" (in Russian). Advances in Gerontology 19:93-96. PMID 17152728
9. Avolio F, et al. 2022. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." International Journal of Molecular Sciences 23(7):3607. PMID 35408963
10. Khavinson VKh, et al. 2014. "Peptide regulation of gene expression and protein synthesis in bronchial epithelium." Lung 192(5):781-791. PMID 25015171
11. Fedoreyeva LI, et al. 2011. "Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA." Biochemistry (Moscow) 76(11):1210-1219. PMID 22117547
12. Khavinson VKh, et al. 2003. "Peptide Epitalon activates chromatin at the old age." Neuro Endocrinology Letters 24(5):329-333. PMID 14647006
13. Kolchina N, et al. 2019. "Systematic search for structural motifs of peptide binding to double-stranded DNA." Nucleic Acids Research 47(20):10553-10563. PMID 31598715
14. Gianfranceschi GL, et al. 1975. "Evidence for the presence in calf thymus of a peptidic factor controlling DNA transcription in vitro." Biochimica et Biophysica Acta 414(1):9-19. PMID 1191703
15. Khavinson VKh, et al. 2003. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine 135(6):590-592. PMID 12937682
16. Al-Dulaimi S, et al. 2025. "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." Biogerontology 26(5):178. PMID 40908429
17. Araj SK, et al. 2025. "Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties." International Journal of Molecular Sciences 26(6):2691. PMID 40141333
18. Anisimov VN, et al. 2003. "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology 4(4):193-202. PMID 14501183
19. Khavinson VKh, Morozov VG. 2003. "Peptides of pineal gland and thymus prolong human life." Neuro Endocrinology Letters 24(3-4):233-240. PMID 14523363